UK small-cap RNS · 1 Sep 2026

Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.

Key = all announcements except routine filings (voting rights, buybacks, holdings, director forms), plus the ones that are part of a situation. Not investment advice.

Sort: Newest · Largest companies

14:48

Ramsdens Holdings RFX £206m
Update On Financing Arrangements
(an indirect wholly-owned subsidiary of FirstCash Holdings, Inc.)

Takeover target +0.5% on the day
13:59

Mode Global Holdings MODE £0.5m
Fundraising, Allotment, TVR & Board Changes Fundraise
Further to its announcement of 21 August 2026, R8 Capital Investments PLC is pleased to announce that the Fundraising has now completed and the Company has allotted and issued 302,393,162 new ordinary shares of £0.0001 each (the "New Ordinary Shares") to the …

Dilutive fundraise +0.0% on the day
09:31

Bytes Technology Group BYIT £1,042m
Holding(s) in Company Holding
07:28

Staffline Group STAF £45m
Director/PDMR Shareholding Director dealing
07:01

Renalytix RENX £40m
Proposed Fundraise Fundraise
Raises about £9.5m at a 44.6% premium, funding the Quest rollout, and converts the Heights Capital bonds to equity so no HCM debt remains. Dilution is large, but the pricing is above market.

Dilutive fundraise £9.5m · 24% of mcapahead of expectationsoutlook mixedfirst in 11 months +0.0% on the day

Moved: Quest national rollout: Agreement signed; integration pending → Funding raised; integration pending · new: Fundraise and debt conversion – Bookbuild open; first tranche admission expected 7 September
07:00

Litigation Capital Management Limited LIT £0.4m
Covenant Waiver Extension
Northleaf extends the covenant waiver by only one month to 30 September, the eighth short extension since December. The 2.00% interest uplift continues and refinancing remains unresolved, so LCM stays dependent on lender forbearance.

Sale process / strategic review +8.2% on the day

Moved: Strategic review: Review ongoing; waiver extended to 31 August → Review ongoing; waiver extended to 30 September
07:00

Bodycote BOY £1,541m
Recommended Cash Acquisition of Bodycote plc Offer
Veritas firm recommended cash offer of 940p (932.8p cash plus 7.2p interim dividend) converts the board-minded-to-recommend proposal into a firm Rule 2.7 offer, at a stated 36.5% premium to the 3-month undisturbed VWAP.

Takeover target £1,640.0m · 106% of mcap +4.6% on the day

Moved: Possible offers for the company: Two proposals; board minded to recommend both → Firm recommended offer announced by Veritas
07:00

Capricorn Energy CNE £291m
Recommended Cash Acquisition of Capricorn by DNO Offer
DNO's recommended cash offer of US$5.214 (384p) per share tops Genel's 357p offer by about 10%, so shareholders get a better price and the unanimously recommended Genel bid is displaced.

Takeover target £292.0m · 100% of mcap +10.2% on the day

Moved: new: DNO offer for the company – Recommended cash offer announced 1 Sep 2026 · Modernised concession agreement ratification: Ratified; ministerial signature still pending → Ratified; ministerial signature still pending
07:00

Renalytix RENX £40m
Collaboration with Quest Diagnostics
Signs the multi-year national distribution deal with Quest the company was seeking, giving access to ordering via about half of US physicians and hospitals; availability only from Q1 2027, so revenue lags.

Transformational contract / build-out outlook positivefirst in 11 months +0.0% on the day

Moved: National distribution agreement: Contract discussions advancing → Agreement signed with Quest Diagnostics (closed) · new: Quest national rollout – Agreement signed; integration pending
07:00

Chariot Limited CHAR £87m
Increasing Exposure to Assets Offshore Angola
Increasing Economic Exposure to Oil-Producing Assets Offshore Angola

Large acquisition / reverse takeover +35.3% on the day

Moved: 'Second Angola Block 14 exposure' is the open 'Angola Block 14 funding deal' - continued · Angola Block 14 funding deal: SPA signed; closing expected H2 2026 → SPA and Framework Agreement signed
07:00

Futura Medical FUM £2.4m
Unaudited Interim Results 2026 Results
Operating loss narrows to £1.2m from £6.7m, but only because £1.4m of the £1.6m revenue is the one-off Haleon settlement; underlying revenue is £0.2m and cash has fallen to £1.24m.

Sale process / strategic review outlook mixed −0.3% on the day

Moved: Going concern and funding: Milestone waived for fee; runway into October 2026 → Material uncertainty; cash £1.06m, runway to October · Strategic review and turnaround: Hybrid model being implemented in the US → Hybrid model executing; MPG US start · Eroxon Intense and WSD4000 development: Eroxon Intense cleared for EEA and UK launch → EU cleared; FDA expected Q4 2026
07:00

Finseta PLC FIN £4.0m
H1 2026 Trading Update Trading update
FY26 now expected below prior Board expectations, with revenue of about £11m. H1 revenue fell and the adjusted EBITDA loss was c. £1.0m, hit by weak demand, Dubai curtailed by conflict, and a lost currency corridor.

Upgrade / downgrade cycle £11.0m · 275% of mcapbelow expectationsoutlook negative, loweredfirst since Oct 2023 −40.5% on the day

Moved: Growth investment and return to cash generation: Fundraise completed; investing, FY25 EBITDA near break-even → Investing; FY26 guidance cut, EBITDA loss in H1 · Dubai and corporate client expansion: Dubai growing ahead of plan; retail endorsement granted → Dubai growing but below expectations
07:00

Ampeak Energy Limited AMP £12m
Ampeak Energy secures investment in AW1 project
Ampeak Energy is pleased to announce that JBR Energy Holdings Ltd ("JB Energy"), a special purpose vehicle owned by various Directors of Jones Bros.

Project milestones £7.8m · 65% of mcapoutlook positive +1.9% on the day

Moved: new: AW1 battery expansion – Nearing financial close; half of sale funds ringfenced · new: AW1 battery construction – Balance of plant and electrical works on schedule
07:00

Wellnex Life Limited WNX £3.7m
Annual Report for Year Ended 30 June 2026 Results
Audited FY26 shows the October 2025 reset working: revenue up 5.1% and the net loss cut by 70.8%. The EBITDA loss fell from about A$12.1m to A$1.7m, although the company is still loss-making.

Disposal of a part (break-up) outlook positivefirst in 6 months +0.0% on the day

Moved: Increase revenue strongly and gross margin in FY26 through a more disciplined tr: on_track → missed – Full-year revenue grew only 5.1% and gross margin rose to 30.2% from 29%, which is not the strong increase promised. · Funding and liquidity position: Binding sale agreed; funding to be resolved at completion → Going-concern uncertainty; relies on Pain Away completion · Sale of Pain Away: Binding agreement signed; awaiting shareholder approval → Binding agreement; awaiting shareholder approval
07:00

Sancus Lending Group Limited LEND £9.3m
Unaudited Interim Results Update Results
H1 operating loss of c. £3.4m is far worse than the £0.9m underlying loss a year earlier, and a c. £14.0m Hawk JV write-down follows. This deepens July's profit shortfall.

New CEO / reset £4.0m · 43% of mcapoutlook mixedfirst since Oct 2023 −19.2% on the day

Moved: Funding facility capacity and maturity: Further £0.5m related-party bond; trading weak through June → £4m related-party liquidity facility signed 28 August · New CEO and profit recovery: Charnley CEO from 10 July; efficiency measures → Strategic plan and Channel Islands review launched
07:00

Taylor Maritime Investments Limited TMIP £52m
Sale of three handysize vessels
Agrees sale of three handysize vessels for about $48.6m, above March book values, leaving two vessels and funding another redemption. Two related-party deals with the CEO's T3 add a governance point, but the Board and sponsor call them fair.

Disposal of a part (break-up) outlook positive +0.0% on the day

Moved: Managed realisation vessel sales: Five vessels left, all on time charter → Three-vessel sale agreed; two vessels left · Third return of capital: $45.0m paid around 24 July 2026 → Third return paid; fourth planned after sales